Skip to main content
    B

    Bio-Rad Laboratories Inc (BIO)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $360.21
    -6.15 (-1.68%)

    Market Cap: $9.85B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Bio-Rad Laboratories Inc (BIO) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Bio-Rad Laboratories (BIO) trades at 37.3x trailing earnings and 3.7x sales. Its P/E of 37.3x is above its 5-year median of 31.2x. Its forward P/E is 38.3x. The median P/E across 9 similar companies is 23.9x.

    Current Multiples

    Its forward P/E is above its trailing P/E, which implies earnings per share about 2.6% lower over the next year. Its free cash flow yield is 4.1%.

    MultipleValue
    P/E (trailing)37.3x
    Forward P/E38.3x
    Price to sales3.7x
    Price to book1.3x
    EV/EBITDA22.2x
    Price to FCF24.5x
    EV/FCF26.4x
    PEG1.2
    FCF yield4.1%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 10.1% below 41.5x, its P/S is 5.1% below 3.9x and its P/B is 23.5% below 1.7x.

    MultipleCurrent5-year median10-year median
    P/E37.3x31.2x41.5x
    P/S3.7x3.8x3.9x
    P/B1.3x1.3x1.7x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 27.4x in 2023 to 191.9x in 2016.

    Year endPriceP/EP/SP/B
    2025$302.9930.5x3.2x1.1x
    2024$328.5131.9x3.6x1.4x
    2023$322.8927.4x3.5x1.1x
    2022$420.4929.5x4.5x1.3x
    2021$755.5748.2x7.7x1.7x
    2020$582.9455.4x6.8x1.8x
    2019$370.0351.8x4.8x1.9x
    2018$232.2240.9x3.0x1.7x
    2017$238.67119.3x3.3x2.5x
    2016$182.28191.9x2.6x2.1x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About BIO

    What is BIO's forward P/E ratio?

    Bio-Rad Laboratories has a forward P/E ratio of 38.3x.

    Is BIO stock overvalued?

    GNG's valuation label for BIO is Fairly valued. Its P/E of 37.3x compares with a median of 23.9x across 9 similar companies.

    What is BIO's price to sales ratio?

    Bio-Rad Laboratories has a price to sales ratio of 3.7x.

    What is Bio-Rad Laboratories's average P/E ratio over 5 years?

    Bio-Rad Laboratories's median P/E over the last 5 years is 31.2x, from 60 month-end values through Oct 2026.

    What is BIO's PEG ratio?

    Bio-Rad Laboratories has a PEG ratio of 1.2.